When Clostridioides difficile infection presents without initial diarrhea, diagnostic delays stretch longer and mortality more than doubles compared with typical presentations.

Clostridioides difficile (C. difficile or C. diff) is a type of bacteria that causes a range of gastrointestinal symptoms, from mild diarrhoea to life-threatening colitis. It affects the colon, which ...

This year in review of 2025 milestones in Clostridioides difficile infection features coverage of research on infection patterns presented at the American Society for Microbiology Microbe 2025 meeting ...

For patients with inflammatory bowel disease (IBD), risk factors associated with Clostridioides difficile infection (CDI) include recent diagnosis, corticosteroid usage, and hospitalization, according ...

Clostridioides difficile is a notoriously nasty intestinal bug, with few effective treatments and no approved vaccines. But the same technology that enabled the first COVID-19 vaccines has shown early ...

UAB researchers developed a novel RNA-based molecular test that more accurately distinguishes active C. diff infection from ...

Signs of inflammatory bowel disease (IBD) activity, shorter duration of IBD, and previous corticosteroid use and hospitalisation were associated with Clostridioides difficile infection in patients ...

In a phase-one human clinical trial, a University of Houston pharmacist researcher has demonstrated that a newer generation tetracycline antibiotic, called Omadacycline, may be a promising tool in ...

An experimental antibiotic called EVG7 has shown promise against gram-positive bacterium Clostridioides difficile, the leading cause of healthcare and antibiotic-associated diarrhea in the US and ...

Idorsia Ltd (SIX: IDIA) today announced additional positive clinical results for IDOR-1134-2831, its vaccine targeting Clostridioides difficile (C. difficile) in a Phase 1 clinical pharmacology trial.